



The Commercial Launch of the first *MET* ex 14 skipping test Archer[®]MET in Japan

TOKYO, August 4, 2020/PRNewswire/ -- ArcherDX, Inc., today announced the Archer[®]MET Companion Diagnostic System (ArcherMET) to detect *MET* exon 14 (*MET*ex14) skipping alterations in patients with advanced non-small cell lung cancer (NSCLC) is commercially available in Japan. ArcherMET was the first next-generation sequencing (NGS) CDx approved to identify *MET* positive patients who may benefit from TEPMETKO[®], the first approved *MET* inhibitor in Japan, indicated for the treatment of unresectable advanced or recurrent NSCLC with *MET*ex14 skipping alterations. Learn more about ArcherMET [here](#).

“We are thrilled the ArcherMET Companion Diagnostic System, *MET*ex14 CDx for patients with NSCLC, is now available in Japan. By leveraging ArcherDX’s proprietary Anchored Multiplex PCR (AMP[™]) chemistry, ArcherMET can efficiently and accurately detect *MET*ex14 skipping mutations by sequencing RNA from tissue and ctDNA from blood samples,” said Jason Myers, Ph.D., Chief Executive Officer and co-founder, ArcherDX. “Because ArcherMET is a test kit that can be easily added to any NSCLC diagnostic workflow, patients can now receive effective therapy sooner. The availability of ArcherMET brings us one step closer to our goal of democratizing precision oncology.”

Lung cancer is one of the most common types of cancer worldwide, with approximately 2 million cases diagnosed in 2018.ⁱ It is also the second most common type of cancer in Japan. Alterations of the *MET* signaling pathway, such as *MET*ex14 skipping alterations, are found in various cancer types, including 3% to 5% of NSCLC cases, and correlate with aggressive tumor behavior and poor clinical prognosis.^{ii,iii,iv}

About TEPMETKO[®]

TEPMETKO is an oral *MET* inhibitor that is designed to inhibit the oncogenic *MET* receptor signaling caused by *MET* (gene) alterations. Discovered and developed in-house at Merck KGaA, Darmstadt, Germany, it has been designed to have a highly selective mechanism of action, with the potential to improve outcomes in aggressive tumors that have a poor prognosis and harbor these specific alterations. In March 2020, TEPMETKO became the first oral *MET* inhibitor indicated for the treatment of advanced NSCLC harboring *MET* gene alterations to receive a regulatory approval, with the Japanese Ministry of Health, Labour and Welfare (MHLW) approval for the treatment of patients with unresectable, advanced or recurrent NSCLC with *MET*ex14 skipping alterations.

About ArcherDX

ArcherDX is a leading genomic analysis company democratizing precision oncology through a suite of products and services that are highly accurate, personal, actionable and easy to use in local settings. Our Archer[®] platform, with our proprietary Anchored Multiplex PCR (AMP[™]) chemistry at the core, has enabled us to develop industry-leading products and services to optimize therapy and enable cancer monitoring across sample types. We develop and commercialize research use only (RUO) products, are developing in vitro diagnostic (IVD) products, and offer services that meet the unique needs of our customers and their clinical applications. Our research product portfolio consists of VariantPlex[®], FusionPlex[®], LiquidPlex[™] and Immunoverse[™]. IVD products currently in development for solid tumor biomarker identification and Personalized Cancer Monitoring (PCM[™]) have both received Breakthrough Device Designation from the FDA. ArcherDX is headquartered in Boulder, Colorado. Learn more at www.archerdx.com and follow [@ArcherDXInc](https://twitter.com/ArcherDXInc) on Twitter, [Facebook](https://www.facebook.com/ArcherDXInc) and [LinkedIn](https://www.linkedin.com/company/archerdx).



For inquiries:

ArcherDX Japan Contact

japan@Archerdx.com

Brand name: ArcherMET Companion Diagnostic System

General name: Somatic cell genetic mutation analysis set (indicated for anti-tumor therapy patient selection)

Approval number: 30200BZI00007000

Foreign approval holder: Archer DX, Inc.

Designated Marketing Authorization Holder: Cobridge KK

info@cobridge.com

ⁱ Bray F, et al. CA Cancer J Clin. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. 2018;68(6):394–424.

<https://doi.org/10.3322/caac.21492> PMID:30207593

ⁱⁱ Reungwetwattana T, et al. Lung Cancer 2017;103:27-37.

ⁱⁱⁱ Mo HN, et al. Chronic Dis Transl Med 2017; 3(3):148-153.

^{iv} Lutterbach B, et al. Cancer Res 2007;67:2081–8.